Monday, September 19, 2016 9:53:12 PM
Biomarkers and Precision Medicine USA Congress Day 2 – 4th October 2016
14.00 – 14.30
Biomarker Development for Intratumoral Gene Therapy with DNA-encoded IL-12
Patient selection biomarkers for low TIL/low anti-PD1 responder population
Pharmacodynamic (PD) biomarkers of effective in-situ vaccination
Robert Pierce, Chief Scientific Strategist, OncoSec Medical
15.30 – 16.00
Panel Discussion- Immuno-oncology Biomarker Development
Challenges in Precision medicine
Status of PDL1 assay and biomarker development and other pathways
Non Respondence of PDL1
Lessons learnt
Chair: Adil Daud, Professor of Medicine, University of California, San Francisco
Panellists:
Robert Pierce, Chief Scientific Strategist, OncoSec Medical Chan Whiting, Associate Director, Aduro Biotech
http://www.biomarkersusa-congress.com/wordpress/wp-content/uploads/2016/09/BF-Biomarkers-and-Precision-Medicine-USA-090916.pdf
NICE!
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM